{"disease":{"id":"reduction-of-stroke-and-systemic-embolism-risk-in-non-valvular-af","name":"reduction of stroke and systemic embolism risk in non valvular af"},"drugs":{"marketed":[{"drug_id":"chembl-chembl48361","indication_name":"Reduction of stroke and systemic embolism risk in non-valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"dabigatran-etexilate","indication_name":"Reduction of stroke and systemic embolism risk in non-valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"dabigatran-etexilate","guideline_body":"FDA label","recommendation":"Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"dabigatran-etexilate","guideline_body":"FDA label","recommendation":"Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated.","line_of_therapy":"2L","evidence_grade":"1A","guideline_year":null},{"drug_id":"dabigatran-etexilate","guideline_body":"FDA label","recommendation":"Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated.","line_of_therapy":"2L","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}